Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HNSA.STthis companyHansa Biopharma AB (publ)	SEK 41.00	-5.22×	-31.35×	12.55×	-6.25×	-323.4%	62.4%	-234.3%	-240.3%	600.2%	-57.8%	-19.7%	-10.49×	-0.48×	-4.43×	1.94×	0.0%	2	-0.05	2	C
ACTI.STActive Biotech AB	SEK 3.44	-166.06×	111.47×	0×	-170.4×	-98.9%	0.0%	0.0%	0.0%	-67.1%	-65.6%	-0.5%	0.03×	1.76×	0×	4.66×	0.0%	3	4.44	2	C+
ALZ.STAlzinova AB (publ)	SEK 0.33	-3.19×	0.68×	0×	-3.24×	-103.5%	0.0%	0.0%	0.0%	-21.5%	-20.9%	-47.5%	0.01×	-0.02×	-27.71×	0.11×	0.0%	3	5.43	2	C+
BINV.STBioInvent International AB (publ)	SEK 3.01	-5.81×	3.47×	8.54×	-4.79×	-4108.5%	100.0%	-155.1%	-147.0%	-59.7%	-62.1%	-13.2%	0.02×	1.05×	0×	5.67×	0.0%	3	-2.93	1	C-
CANTA.STCantargia AB (publ)	SEK 1.57	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
DMYD-B.STDiamyd Medical AB (publ)	SEK 0.97	-0.58×	0.61×	310.44×	0.62×	98.3%	-478.8%	-54562.9%	-53583.4%	-104.9%	-78.6%	-132.6%	0×	1.21×	-73.88×	9.08×	0.0%	3	-0.68	2	B-
Peer median	—	-3.19×	3.47×	3.28×	-3.24×	-98.9%	0.0%	0.0%	0.0%	-59.7%	-62.1%	-13.2%	0.01×	1.05×	0×	5.67×	0.0%	3	3.27	2	—